Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Fusion Proteins, bcr-abl
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles

abstract

  • Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).

publication date

  • June 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa055229

PubMed ID

  • 16775234

Additional Document Info

start page

  • 2531

end page

  • 41

volume

  • 354

number

  • 24